Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Immatics ( (IMTX) ) has issued an announcement.
Immatics N.V. announced that Bristol Myers Squibb has decided to terminate their collaboration agreements related to allogeneic programs and a specific target under a multi-target TCR-T collaboration. Despite the termination effective March 12, 2025, Immatics will retain the upfront payments received, while their 2019 strategic collaboration with BMS remains intact, potentially affecting their strategic positioning and future operations.
More about Immatics
Immatics N.V. operates in the biotechnology industry, focusing on the development of T-cell receptor-based therapies for cancer treatment. The company’s primary products include allogeneic programs and multi-target TCR-T strategies, with significant collaborations in place with major pharmaceutical companies.
YTD Price Performance: -29.63%
Average Trading Volume: 614,241
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $884.4M
See more insights into IMTX stock on TipRanks’ Stock Analysis page.
